BRC branches into MS

The Brain Resource Company (ASX:BRC) is to supply its services to a Schering Israel funded Multiple Sclerosis study.

The study is being conducted by Professor Ariel Miller at the Technion-Israel Institute of Technology Carmel Medical Centre in Haifa and will use BRC's standardised cognitive test battery accessed through an IBM touch screen.

"The study will use our services to look at the effects of MS on memory attention, sensory motor skills, speed of decision making and planning capacities. The data is also going to be compared to the 1000 so subjects in the brain resource international data base," said BRC's chairman and CEO, Evian Gordon.

"This agreement is significant in many respects as it furthers our application to multiple sclerosis and is our first pharmaceutical trial sourced out of Israel. This builds on our continued momentum in Israel where there is now a growing number of users. It is a 12 month trial which is due to commence shortly."

"MS also adds to the growing profile of disorders BRC methodically has been used in. We are now in a number of different disorders including: depression, Alzheimer's dementia, ADHA [attention deficit hyper attention disorder], schizophrenia and PTSD [post traumatic stress disorder]."

BRC's standardised cognitive test battery is currently used in over 70 sites around the world including the US Europe, Australia and BRC is an IBM advanced business partner.

Including this study, BRC has now serviced 7 of the top 15 global pharmaceutical companies and brings the total number of trials to date to 18.